Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 43.7 USD -1.18%
Market Cap: 4B USD
Have any thoughts about
Ultragenyx Pharmaceutical Inc?
Write Note

Gross Margin
Ultragenyx Pharmaceutical Inc

86.3%
Current
91%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.3%
=
Gross Profit
450.9m
/
Revenue
522.7m

Gross Margin Across Competitors

Country US
Market Cap 4.1B USD
Gross Margin
86%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 310.3B USD
Gross Margin
67%
Country US
Market Cap 141.6B USD
Gross Margin
60%
Country US
Market Cap 115.3B USD
Gross Margin
78%
Country US
Market Cap 102.4B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 134.4B AUD
Gross Margin
52%
Country US
Market Cap 77.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 35.8B EUR
Gross Margin
89%
No Stocks Found

Ultragenyx Pharmaceutical Inc
Glance View

Market Cap
4B USD
Industry
Biotechnology

Ultragenyx Pharmaceutical Inc. emerges from the bustling biotech landscape as a company uniquely focused on addressing the unmet needs of rare and ultra-rare genetic diseases. Founded in 2010 by Dr. Emil Kakkis, who has been instrumental in the development of treatments for genetic conditions, Ultragenyx operates with a singular vision: to transform lives through the development and commercialization of novel therapies. The company works diligently at the intersection of biotechnology and medicine, where it utilizes advanced platforms, including gene therapy and biologics, to innovate treatments that specifically target the root causes of these rare diseases. By focusing on conditions with limited treatment options, Ultragenyx not only taps into niche markets but also helps forge new pathways in medical research. Financially, Ultragenyx capitalizes on its comprehensive portfolio of products and promising pipeline of candidates in various stages of development. The company's revenue model is primarily driven by the successful commercialization of its approved therapies, which provide life-changing benefits to patients with rare diseases. This revenue stream is augmented by strategic partnerships and collaborations, which help to mitigate costs and share risks associated with the high stakes of drug development. R&D investments are substantial, reflecting the company's commitment to innovation and long-term growth. In a sector characterized by high research costs and regulatory hurdles, Ultragenyx's targeted approach to niche diseases positions it as a potentially resilient player, with its revenues bolstered by a commitment to addressing critical patient needs.

RARE Intrinsic Value
63.72 USD
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.3%
=
Gross Profit
450.9m
/
Revenue
522.7m
What is the Gross Margin of Ultragenyx Pharmaceutical Inc?

Based on Ultragenyx Pharmaceutical Inc's most recent financial statements, the company has Gross Margin of 86.3%.